Nikos G Oikonomakos,László Somsák
Nikos G Oikonomakos
The regulation of glycogen metabolism is a major therapeutic strategy for blood glucose control in type 2 diabetes. Because glycogen phosphorylase catalyzes the first step in the phosphorolysis of glycogen, it has become a potential key tar...
Peter J Elliott,Michael Jirousek
Peter J Elliott
Sirtuins represent a novel family of enzymes that are collectively well situated to help regulate nutrient sensing and utilization, metabolic rate and ultimately metabolic disease. Activation of one of these enzymes, SIRT1, leads to enhance...
Francesco Locatelli,Monica Limardo,Giuseppe Pontoriero
Francesco Locatelli
A large number of patients with chronic kidney disease are affected by secondary hyperparathyroidism. The related mineral metabolism abnormalities are associated with an increased relative risk of morbidity and mortality. The management of ...
Sara Danzi,Irwin Klein
Sara Danzi
Thyroid hormone deficiency has been recognized and treated with various forms of thyroid hormone replacement over the last century. Since the 1950s, synthetic L-thyroxine has been the therapy of choice. However, there is now recognition tha...
The success of bariatric surgery as treatment of type 2 diabetes should be a call to revitalize anti-obesity drug discovery and development [0.03%]
减重手术成功治疗2型糖尿病应当激励肥胖药物的研发
Terry J Opgenorth
Terry J Opgenorth
Prasugrel, a third generation thienopyridine and potent platelet inhibitor [0.03%]
普拉格雷：第三代噻吩并吡啶类血小板强力抑制剂
Paul A Gurbel,Udaya S Tantry
Paul A Gurbel
Eli Lilly & Co and Daiichi Sankyo Co Ltd are developing prasugrel, a third generation thienopyridine derivative. Prasugrel is in phase III clinical trials in Western Europe and Japan, and is awaiting regulatory approval in the US for the tr...
Rhucin, a recombinant C1 inhibitor for the treatment of hereditary angioedema and cerebral ischemia [0.03%]
重组C1抑制剂Rhucin治疗遗传性血管水肿和脑缺血
Hilary Longhurst
Hilary Longhurst
Pharming NV and Esteve are developing Rhucin, a recombinant human C1 esterase inhibitor. Rhucin is currently undergoing phase III clinical trials in North America and is awaiting regulatory approval in Western Europe for the treatment of pr...
Ilepatril (AVE-7688), a vasopeptidase inhibitor for the treatment of hypertension [0.03%]
用于治疗高血压的血管酶抑制剂伊肽洛尔(AVE-7688)
Reza Tabrizchi
Reza Tabrizchi
sanofi-aventis (formerly Aventis Pharma AG) is developing ilepatril (AVE-7688), a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, for the potential treatment of hypertension and diabetic nephropathy. Ilepatril is cur...
11beta-hydroxysteroid dehydrogenase type 1 inhibitors for metabolic syndrome [0.03%]
11β-羟 steroid脱氢酶类型1抑制剂用于代谢综合征
Christine G Schnackenberg
Christine G Schnackenberg
The metabolic syndrome is a constellation of interrelated metabolic risk factors that appear to promote the development of diabetes and cardiovascular disease. These risk factors include abdominal obesity, insulin resistance, hypertension a...
Feng Zhu,Zihua Zhou,Yuhua Liao
Feng Zhu
With increased understanding of the pharmacology of the renin-angiotensin system (RAS), many researchers have explored immunological approaches to inhibit components of the RAS for the treatment of hypertension. Active and passive immunizat...